Results 201 to 210 of about 23,427,651 (311)

SNP Analysis Reveals Novel Insights into the Genetic Diversity of Colombian <i>Vaccinium meridionale</i>. [PDF]

open access: yesGenes (Basel)
Sepúlveda J   +9 more
europepmc   +1 more source

Defect‐engineered tungsten oxide nanowires as redox‐metabolic nanozymes for gut inflammation‐infection syndromes

open access: yesBMEMat, EarlyView.
Defect‐engineered WO3 nanowires serve as a multifunctional nanozyme platform to treat IBD complicated by Salmonella co‐infection. By integrating catalytic ROS/RNS scavenging and targeted metabolic interference of pathogens via molybdenum substitution, these nanowires effectively resolve intestinal oxidative stress, inhibit infection, and restore ...
Yifan Yuan   +13 more
wiley   +1 more source

Genome-Wide SNP Analysis Reveals the Unique Genetic Diversity Represented by Fat-Tailed Coarse-Wooled Sheep Breeds of Kazakhstan. [PDF]

open access: yesBiology (Basel)
Dossybayev K   +7 more
europepmc   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz   +5 more
wiley   +1 more source

Leveraging LASSO-based methodologies for enhanced SNP analysis in plant genomes. [PDF]

open access: yesBioinform Adv
Puthiyedth N   +5 more
europepmc   +1 more source

Characterization of NAT2 Using Long‐Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The NAT2 pharmacogene is essential in drug metabolism, particularly for aromatic amines and hydrazines. Genetic variations in NAT2 categorize individuals as rapid, intermediate, or poor metabolizers based on their acetylation capacity to inform dosing guidelines.
Shobana John   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy